The alkylating agent ifosfamide is an anti-neoplastic used to treat various pediatric and adult malignancies. Its potential urologic toxicities include glomerulopathy, tubulopathy and hemorrhagic cystitis. This report describes a case of proximal renal tubular dysfunction and hemorrhagic cystitis in a 67-year-old male given ifosfamide for epitheloid sarcoma. He was also receiving an oral hypoglycemic agent for type 2 diabetes mellitus and had a baseline glomerular filtration rate of 51.5 mL/min/1.73 m². Despite mesna prophylaxis, the patient experienced dysuria and gross hematuria after a single course of ifosfamide plus adriamycin. The abrupt renal impairment and serum/urine electrolyte imbalances that ensued were consistent with Fanconi's syndrome. However, normal renal function and electrolyte status were restored within 14 days, simply through supportive measures. A score of 8 by Naranjo adverse drug reaction probability scale indicated these complications were most likely treatment-related, although they developed without known predisposing factors. The currently undefined role of diabetic nephropathy in adult ifosfamide nephrotoxicity merits future investigation.

Citations

Citations to this article as recorded by  

• Ifosfamide-induced nephrotoxicity in oncological patients
  Juan Eduardo Quiroz-Aldave, María Del Carmen Durand-Vásquez, Freddy Shanner Chávez-Vásquez, Alexandra Noelia Rodríguez-Angulo, Sonia Elizabeth Gonzáles-Saldaña, Carlos César Alcalde-Loyola, Julia Cristina Coronado-Arroyo, Francisca Elena Zavaleta-Gutiérre
  Expert Review of Anticancer Therapy.2024; 24(1-2): 5.     CrossRef
• Conditioning Regimens for Relapsed/Refractory Lymphoma Patients Undergoing Autologous Stem Cell Transplantation: BEAM Versus High Dose ICE
  Ahmet Kursad Gunes, Simten Dagdas, Funda Ceran, Mehmet Ali Ucar, Mesude Falay, Cenk Sunu, Meltem Ayli, Nurullah Zengin, Gulsum Ozet
  Indian Journal of Hematology and Blood Transfusion.2021; 37(1): 82.     CrossRef
• Cancer treatment-induced bone loss (CTIBL): Pathogenesis and clinical implications
  S. D’Oronzo, S. Stucci, M. Tucci, F. Silvestris
  Cancer Treatment Reviews.2015; 41(9): 798.     CrossRef
• Tubulointerstitial nephritis and cancer chemotherapy: update on a neglected clinical entity
  M. Airy, R. Raghavan, L. D. Truong, G. Eknoyan
  Nephrology Dialysis Transplantation.2013; 28(10): 2502.     CrossRef